GlassScriptPhysician profile
Nancy Leigh Mcintyre
NPI 1952628182
$7,821.71
in general payments reported to CMS, 2019-2025
42 companies · $796 in 2025
The $796 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $33.16 · 2021: $1,381 · 2022: $1,873 · 2023: $1,822 · 2024: $1,916 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,532 · Education: $2.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,531.92 |
| Education | $2.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,243.95 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $884.40 | 2021-2025 | |
| Lilly USA, LLC | $881.65 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $763.25 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $511.43 | 2021-2025 | |
| Inspire Medical Systems, INC. | $461.75 | 2023-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $413.13 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Biohaven Pharmaceutical Holding Company LTD. | $294.28 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $262.32 | 2021 | |
| Amgen INC. | $214.13 | 2022-2024 | Otezla, Repatha |
| Shield Therapeutics INC | $175.37 | 2022-2025 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $159.07 | 2021-2023 | Trintellix |
| Hikma Pharmaceuticals USA | $137.31 | 2021-2024 | Ryaltris, Kloxxado, Mitigare |
| Corium, LLC | $131.91 | 2021-2023 | Azstarys |
| Dexcom, INC. | $117.99 | 2022-2024 | Dexcom G6 Transmitter |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Mcintyre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.